• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Time to rethink the reported disease-modifying treatment effects on cognitive outcomes: Methods and interpretative caveats.

作者信息

Labiano-Fontcuberta Andrés, Monreal Enric, Benito-León Julián

机构信息

Department of Neurology, University Hospital12 de Octubre, Madrid, Spain.

Department of Neurology, University Hospital Ramón y Cajal, Universidad de Alcalá, Ramón y Cajal Institute for Health Research (IRYCIS), Spanish Network of Multiple Sclerosis (REEM), Madrid, Spain.

出版信息

Front Neurol. 2022 Sep 1;13:995690. doi: 10.3389/fneur.2022.995690. eCollection 2022.

DOI:10.3389/fneur.2022.995690
PMID:36119690
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9474887/
Abstract
摘要

相似文献

1
Time to rethink the reported disease-modifying treatment effects on cognitive outcomes: Methods and interpretative caveats.是时候重新思考所报道的疾病修饰治疗对认知结果的影响了：方法和解释性注意事项。
Front Neurol. 2022 Sep 1;13:995690. doi: 10.3389/fneur.2022.995690. eCollection 2022.
2
Rethink My Drink: study protocol for a 12-month randomised controlled trial comparing a brief internet-delivered intervention to an online patient information booklet in reducing risky alcohol consumption among older adults in Australia.重新思考饮酒：一项为期 12 个月的随机对照试验研究方案，比较一种简短的互联网干预措施和在线患者信息手册，以减少澳大利亚老年人的危险饮酒行为。
Addiction. 2022 Mar;117(3):815-825. doi: 10.1111/add.15672. Epub 2021 Sep 20.
3
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.大麻素用于进行性炎症性脑病（CUPID）试验：一项随机双盲安慰剂对照平行组多中心试验及大麻素延缓多发性硬化症进展的经济学评估。
Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.
4
Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a randomized controlled trial.多发性硬化的神经心理学管理：评估在家中自我使用的监督和定制认知康复计划（SEPIA）：一项随机对照试验的方案。
Trials. 2019 Oct 29;20(1):614. doi: 10.1186/s13063-019-3715-7.
5
Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.团体认知康复对多发性硬化症患者生活质量的心理影响的随机对照试验。
Health Technol Assess. 2020 Jan;24(4):1-182. doi: 10.3310/hta24040.
6
Exercise training and cognition in multiple sclerosis: The GET Smart trial protocol.多发性硬化症的运动训练与认知：GET Smart 试验方案。
Contemp Clin Trials. 2021 May;104:106331. doi: 10.1016/j.cct.2021.106331. Epub 2021 Feb 27.
7
Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.一线疾病修正治疗的多发性硬化症患者的认知功能障碍：一项使用BICAMS成套测验的多中心对照研究。
Neurol Sci. 2017 Feb;38(2):337-342. doi: 10.1007/s10072-016-2775-7. Epub 2016 Nov 24.
8
Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.在多发性硬化症的 Alemtuzumab 治疗的头 2 年中，客观评估生理、身体和认知功能以及患者报告的结果：一项前瞻性观察研究。
J Neurol. 2022 Sep;269(9):4895-4908. doi: 10.1007/s00415-022-11134-7. Epub 2022 Apr 28.
9
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial.不同类型β-干扰素治疗多发性硬化症患者的认知功能障碍：一项随机临床试验。
J Neurol Sci. 2014 Jul 15;342(1-2):16-20. doi: 10.1016/j.jns.2014.01.038. Epub 2014 Feb 4.
10
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.复发缓解型多发性硬化症的疾病修正治疗与认知：一项荟萃分析。
Neurology. 2020 Jun 2;94(22):e2373-e2383. doi: 10.1212/WNL.0000000000009522. Epub 2020 May 19.

引用本文的文献

1
Uncovering heterogeneous cognitive trajectories in relapsing-remitting multiple sclerosis: a longitudinal study.揭示复发缓解型多发性硬化症中的异质性认知轨迹：一项纵向研究。
Acta Neurol Belg. 2025 Apr;125(2):519-530. doi: 10.1007/s13760-025-02754-7. Epub 2025 Mar 15.
2
Attitudes of Neurologists Toward Serum Neurofilament Light-Chain Testing in the Management of Relapsing-Remitting Multiple Sclerosis with Cognitive Impairment.神经科医生对血清神经丝轻链检测在伴认知障碍的复发缓解型多发性硬化管理中的态度
J Pers Med. 2025 Feb 14;15(2):69. doi: 10.3390/jpm15020069.
3
Detecting isolated cognitive relapses in persons with MS.检测多发性硬化症患者的孤立性认知发作。
Mult Scler. 2023 Dec;29(14):1786-1794. doi: 10.1177/13524585231201219. Epub 2023 Sep 30.
4
High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis.κ 轻链游离合成水平升高可预测复发缓解型多发性硬化症的认知能力下降。
Front Immunol. 2023 Jan 20;14:1106028. doi: 10.3389/fimmu.2023.1106028. eCollection 2023.

本文引用的文献

1
The effect of timing of high-efficacy therapy on processing speed performance in multiple sclerosis.高效疗法的时机对多发性硬化症处理速度表现的影响。
Mult Scler Relat Disord. 2022 Aug;64:103959. doi: 10.1016/j.msard.2022.103959. Epub 2022 Jun 10.
2
Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study.基于智能手机的观察性研究中移动认知、灵巧性和移动能力测试对多发性硬化症患者的练习效应：数据分析。
J Med Internet Res. 2021 Nov 18;23(11):e30394. doi: 10.2196/30394.
3
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.使用可靠变化方法解读复发型多发性硬化患者符号数字模态测验的变化。
Mult Scler. 2022 Jun;28(7):1101-1111. doi: 10.1177/13524585211049397. Epub 2021 Oct 6.
4
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.奥扎莫德对复发型多发性硬化症符号数字模式测验表现的影响。
Mult Scler Relat Disord. 2021 Feb;48:102673. doi: 10.1016/j.msard.2020.102673. Epub 2020 Dec 10.
5
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?符号数字模态测验在继发进展型多发性硬化症中是否有用？
Eur J Neurol. 2021 Jun;28(6):2115-2120. doi: 10.1111/ene.14732. Epub 2021 Jan 24.
6
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.西尼莫德与继发进展型多发性硬化症认知功能：EXPAND 二次分析。
Neurology. 2021 Jan 19;96(3):e376-e386. doi: 10.1212/WNL.0000000000011275. Epub 2020 Dec 16.
7
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.复发缓解型多发性硬化症的疾病修正治疗与认知：一项荟萃分析。
Neurology. 2020 Jun 2;94(22):e2373-e2383. doi: 10.1212/WNL.0000000000009522. Epub 2020 May 19.
8
Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis.富马酸二甲酯两年治疗对复发缓解型多发性硬化症患者认知和功能损害的影响。
Neurol Sci. 2020 Nov;41(11):3185-3193. doi: 10.1007/s10072-020-04320-w. Epub 2020 May 1.
9
Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.阿仑单抗可改善活动性多发性硬化症患者的认知处理速度——一项纵向观察研究
Front Neurol. 2018 Jan 16;8:730. doi: 10.3389/fneur.2017.00730. eCollection 2017.
10
Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.一年纳武利尤单抗治疗后的认知功能：一项非随机临床试验。
Acta Neurol Scand. 2018 Jan;137(1):117-124. doi: 10.1111/ane.12833. Epub 2017 Sep 13.